In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
After finishing at $13.29 in the prior trading day, Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) closed at $13.42, up 0.98%. In other words, the price has increased by $0.98 from its previous closing price. On the day, 1.2 million shares were traded. AMLX stock price reached its highest trading level at $13.71 during the session, while it also had its lowest trading level at $13.22.
Ratios:
Our goal is to gain a better understanding of AMLX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.72 and its Current Ratio is at 8.72. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
On June 24, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $17.
On June 17, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $12.Citigroup initiated its Buy rating on June 17, 2025, with a $12 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 30 ’25 when Klee Justin B. sold 29,975 shares for $14.38 per share. The transaction valued at 430,952 led to the insider holds 3,325,301 shares of the business.
Mazzariello Gina sold 8,828 shares of AMLX for $128,669 on Sep 30 ’25. The Chief Legal Officer now owns 148,141 shares after completing the transaction at $14.58 per share. On Sep 30 ’25, another insider, FRATES JAMES M, who serves as the Chief Financial Officer of the company, sold 10,558 shares for $14.65 each. As a result, the insider received 154,650 and left with 280,430 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMLX now has a Market Capitalization of 1431476992 and an Enterprise Value of 1021762944. Its current Enterprise Value per Revenue stands at -4103.466 whereas that against EBITDA is -5.205.
Stock Price History:
The Beta on a monthly basis for AMLX is -0.32, which has changed by 3.357143 over the last 52 weeks, in comparison to a change of 0.17904854 over the same period for the S&P500. Over the past 52 weeks, AMLX has reached a high of $15.15, while it has fallen to a 52-week low of $2.60. The 50-Day Moving Average of the stock is 30.69%, while the 200-Day Moving Average is calculated to be 123.26%.
Shares Statistics:
The stock has traded on average 1.65M shares per day over the past 3-months and 1948440 shares per day over the last 10 days, according to various share statistics. A total of 89.16M shares are outstanding, with a floating share count of 79.58M. Insiders hold about 25.39% of the company’s shares, while institutions hold 70.85% stake in the company. Shares short for AMLX as of 1757894400 were 8774952 with a Short Ratio of 5.31, compared to 1755216000 on 7433417. Therefore, it implies a Short% of Shares Outstanding of 8774952 and a Short% of Float of 8.92.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 7.0 analysts currently analyzing and rating the stock of Amylyx Pharmaceuticals Inc (AMLX).The consensus estimate for the next quarter is -$0.39, with high estimates of -$0.06 and low estimates of -$0.51.
Analysts are recommending an EPS of between -$1.17 and -$2.02 for the fiscal current year, implying an average EPS of -$1.66. EPS for the following year is -$1.48, with 7.0 analysts recommending between -$0.76 and -$1.97.
